-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 11, Prologue Pharmaceuticals stated that its wholly-owned subsidiary Zhejiang Jutai Pharmaceutical Co.
, Ltd.
received the "Approval Notice for Supplementary Drug Application" approved and issued by the National Medical Products Administration on ceftazidime for injection
.
Ceftazidime is a powerful and broad-spectrum third-generation cephalosporin antibiotic.
Compared with the first and second-generation cephalosporins, the activity against gram-negative bacteria and the stability of β-lactamase are enhanced, and it is comparable to other third-generation cephalosporins.
It has the strongest effect on Pseudomonas aeruginosa, and is often used as one of the preferred drugs for sensitive bacteria
.
Ceftazidime for injection belongs to the 2020 edition of the National Medical Insurance Category B and the 2018 edition of the National Essential Drug List
Ceftazidime for injection is the fifth batch of national drug centralized procurement catalog varieties.
The company's approval of the product quality and efficacy consistency evaluation indicates that the company has obtained the qualification to participate in the centralized procurement declaration
.
According to relevant national policies, the company and all members of the board of directors guarantee that the content of the information disclosed is true, accurate, and complete, and there are no false records, misleading statements or major omissions
